Etanercept

Name: Etanercept Y10005702
SKU: 08001602_Y10005702
Price: 237.40 EUR
Availability: InStock

Therapeutic Etanercept antibody from the original Enbrel® and biosimilar commercial drugs.

Showing all 11 results

Filter our product list:

CoA

Product Batch	Antigen	Molecular Class	Drug Brand	Product Concentration	CoA	Quantity per vial	Storage Temperature	Expiry Date	Price from
Etanercept 2110190088	TNF alpha	Biosimilar , Fusion protein	Erelzi®	50 mg/mL	–	4 mg	-80°C	2023.04	272,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept FL6599	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	6 mg	-80°C	2024.01	274,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept GR206474	TNF alpha	Biosimilar , Fusion protein	Benepali®	50 mg/mL	–	4 mg	-80°C	2023.11	272,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept S67398	TNF alpha	Fusion protein	Enbrel®	25 mg/mL	–	2 mg	-80°C	2019.02	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept T21782	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	2019.04	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept T64915	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	2019.06	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept W02981	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	2019.08	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept W32559	TNF alpha	Fusion protein	Enbrel®	25 mg/mL	–	2 mg	-80°C	2019.12	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept W42283	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	2019.10	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept X44248	TNF alpha	Fusion protein	Enbrel®	50 mg/mL	–	2 mg	-80°C	2020.04	197,00 €	view product Max: 10 Min: 2 Step: 1
Etanercept Y10005702	TNF alpha	Biosimilar , Fusion protein	Nepexto®	50 mg/mL	–	4 mg	-80 °C	2023.08	237,40 €	view product Max: 10 Min: 2 Step: 1

Not looking for Etanercept?

Search our therapeutic molecules product database

Enbrel® / Etanercept Reference Product

Drug name	Enbrel®
INN	Etanercept
API type	Etanercept is a human tumour necrosis factor receptor p75 Fc fusion protein produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian expression system. Etanercept is a dimer of a chimeric protein genetically engineered by fusing the extracellular ligand binding domain of human tumour necrosis factor receptor-2 (TNFR2/p75) to the Fc domain of human IgG1. This Fc component contains the hinge, CH2and CH3regions, but not the CH1region of IgG1. Etanercept contains 934amino acids and has an apparent molecular weight of approximately 150 kilodaltons. The specific activity of etanercept is 1.7x 106units/mg.
Pharmacotherapeutic group	Immunosuppressants, Tumour Necrosis Factor alpha (TNF-α) inhibitors
ATC code	L04AB01
Target of antibody	TNF-α; Synonyms: DIF, TNF-alpha, TNFA, TNFSF2, RATTNF, Tnfa, tnf, TNF-a, TNFalpha, Tnfsf1a, TNFa, cTNF, Tnf-alpha, tnfa-like, TNF-ALPHA, dif, tnfa, xtnf, tnfsf2, tnf-alpha, Cachectin
General function
Short description	Tumour necrosis factor (TNF) is a dominant cytokine in the inflammatory process of rheumatoid arthritis. Elevated levels of TNF are also found in the synovium and psoriatic plaques of patients with psoriatic arthritis and in serum and synovial tissue of patients with ankylosing spondylitis. In plaque psoriasis, infiltration by inflammatory cells, including T-cells, leads to increased TNF levels in psoriatic lesions compared with levels in uninvolved skin. Etanercept is a competitive inhibitor of TNF binding to its cell surface receptors, and thereby inhibits the biological activity of TNF. TNF and lymphotoxin are pro-inflammatory cytokines that bind to two distinct cell surface receptors: the 55- kilodalton (p55) and 75-kilodalton (p75) tumour necrosis factor receptors (TNFRs). Both TNFRs exist naturally in membrane-bound and soluble forms. Soluble TNFRs are thought to regulate TNF biological activity. TNF and lymphotoxin exist predominantly as homotrimers, with their biological activity dependent on cross-linking of cell surface TNFRs. Dimeric soluble receptors, such as etanercept, possess a higher affinity for TNF than monomeric receptors and are considerably more potent competitive inhibitors of TNF binding to its cellular receptors. In addition, use of an immunoglobulin Fc region as a fusion element in the construction of a dimeric receptor imparts a longer serum half-life.
Pharmacodynamic properties (Mechanism of action; Source EMA document)	Much of the joint pathology in rheumatoid arthritis and ankylosing spondylitis and skin pathology in plaque psoriasis is mediated by pro-inflammatory molecules that are linked in a network controlled by TNF. The mechanism of action of etanercept is thought to be its competitive inhibition of TNF binding to cell surface TNFR, preventing TNF-mediated cellular responses by rendering TNF biologically inactive. Etanercept may also modulate biologic responses controlled by additional downstream molecules (e.g., cytokines, adhesion molecules, or proteinases) that are induced or regulated by TNF.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)
Original license holder
Marketing authorisation numbers	EU/1/99/126/001 - 022
Marketing authorisation holder	Pfizer Limited Ramsgate Road Sandwich Kent CT13 9NJ United Kingdom
Name of the manufacturer of the biological active substance	Boehringer Ingelheim Pharma KG Birkendorfer Strasse 65 D-88397 Biberach an der Riss Germany Pfizer Ireland Pharmaceuticals Grange Castle Business Park Clondalkin Dublin 22 Ireland
Name and address of the manufacturer(s) responsible for batch release	Wyeth Pharmaceuticals New Lane Havant Hampshire, PO9 2NG United Kingdom
Max shelf life	48 months
Storage conditions	2°C – 8°C
List of excipients	Powder: Mannitol (E421) Sucrose Trometamol Solvent: Water for injections